Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
”Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease is a rare but clinically significant complement-mediated autoimmune hemolytic anemia driven by cold-reactive IgM antibodies.
What makes CAD particularly important is its dual presentation: chronic hemolysis alongside cold-induced circulatory symptoms such as acrocyanosis and Raynaud-like changes.
Diagnosis requires a high index of suspicion, with a characteristic C3d-positive direct antiglobulin test and evidence of complement activation.
Management has evolved significantly in recent years.
While cold avoidance and rituximab-based therapy remain important, targeted complement inhibition (e.g. sutimlimab) is transforming outcomes in selected patients.
Early recognition is key to preventing complications and improving quality of life.”
Stay updated with Hemostasis Today.
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
-
May 18, 2026, 16:34Serah. N. Gathu: Gaining Valuable Updates on ACS Management at the Africa STEMI Conference
-
May 18, 2026, 16:34Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
-
May 18, 2026, 16:33Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
-
May 18, 2026, 16:32Michael Lichardi: New Publication on Complex Anticoagulation Management in Critical Care
-
May 18, 2026, 16:28Reza Shojaei: The Global Plasma-to-Ig Supply Chain
-
May 18, 2026, 16:01Abdul Mannan: The Hardest Conversations in Myelofibrosis
-
May 18, 2026, 15:57Bridging Innovation and Access at the WFH 2026 World Congress – South African Haemophilia Foundation
-
May 18, 2026, 15:55Pierre François Sabouret: Network Meta-Analysis of Antithrombotic Therapy in Ischemic Stroke Patients